Yahoo
Tokyo - Delayed Quote JPY

Heartseed Inc. (219A.T)

2,928.00 +228.00 (+8.44%)
As of 1:40:57 PM GMT+9. Market Open.
Chart Range Bar
Loading chart for 219A.T
  • Previous Close 2,700.00
  • Open 2,680.00
  • Bid 2,927.00 x --
  • Ask 2,928.00 x --
  • Day's Range 2,655.00 - 2,978.00
  • 52 Week Range 1,365.00 - 3,210.00
  • Volume 360,400
  • Avg. Volume 503,510
  • Market Cap (intraday) 67.044B
  • Beta (5Y Monthly) -0.80
  • PE Ratio (TTM) 354.17
  • EPS (TTM) 8.27
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 3,700.00
  • Moby Rating Neutral

Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.

www.heartseed.jp

--

Full Time Employees

October 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

219A.T
62.36%
Nikkei 225 (^N225)
17.62%

1-Year Return

219A.T
65.76%
Nikkei 225 (^N225)
17.77%

3-Year Return

219A.T
89.21%
Nikkei 225 (^N225)
81.37%

5-Year Return

219A.T
89.21%
Nikkei 225 (^N225)
102.18%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 465M
Earnings -58M
Profit Margin -12.47%

Q1

FY26

0
100M
200M
300M
400M
-12.5%

Analyst Insights

View More

Analyst Price Targets

3,700.00
3,700.00 Average
2,928.00 Current
3,700.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.58%

  • Return on Assets (ttm)

    5.97%

  • Return on Equity (ttm)

    8.35%

  • Revenue (ttm)

    3.03B

  • Net Income Avi to Common (ttm)

    592.5M

  • Diluted EPS (ttm)

    8.27

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.34B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: